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Abstract
This review explores the functional relationships between salivary glands and adipose tissue. since salivary glands, and in par-
ticular the submandibular glands, exert profound systemic effects on organs and inflammatory responses outside the gastro-
intestinal tract, the question arises if these glands also impact the body’s physiological response to increases in adipose tissue 
deposition and secretion. and, if the adipose tissue deposition and secretion impact the salivary gland’s physiological response. 
To date the evidence is relatively weak that salivary glands significantly impact obesity, or that their function is dramatically 
altered by obesity, and that the measurement of metabolic peptides in saliva will lead to diagnostic and treatment strategies 
for obesity and related cardiometabolic diseases. although obesity detrimentally impacts oral health causative linkages and 
associations have not been conclusively made between periodontitis and obesity. The most intriguing connections between 
adipobiology and saliva (or salivary glands) have emerged from unexpected quarters. It was recently reported that adiponectin, 
resistin and visfatin (adipose tissue-derived signalling proteins collectively termed adipokines) are found in saliva and that their 
amount correlates with that of circulating level of these adipokines. These observations suggest that the introduction of salivary 
determinations of adipokines may contribute to the study of pathogenesis of various obesity-related diseases. Receptors for 
adipokines and obesity-related hormones, especially for polypeptide y (pyy(3-36), in the mouth and in particular the taste buds, 
may be a primary signal for satiety. This observation offers new avenues for investigating the physiology of satiety along with 
potential treatment strategies for obesity. another unexpected finding, and to date unrelated to obesity – the transplantation 
of adipose-derived stromal cells has the potential to restore salivary gland function after their destruction by radiation therapy.
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background
The major salivary glands are the parotid, submandibular, and 
sublingual glands, although numerous (>600), minor salivary 
glands are found within the submucosa and mucosa of the lips, 
inner cheek area, and other parts of the oral cavity. Von Ebner’s 
glands, another salivary gland also called gustatory glands, are 
found in circumvallate papillae of the tongue and facilitate lipid 
hydrolysis and taste. The salivary glands make saliva a complex 
mixture of more than 2000 products in the peptidome, of which 
only a quarter are actually derived from the salivary glands in-
dicating that other cells in the oral cavity (e.g. epithelial cells, 
leukocytes, etc.) make a significant quantitative contribution of 
proteins to saliva (1). Although salivary secretions are primar-
ily associated with maintaining a moist mouth and digestion of 
starches (amylase) and lipids (lingual lipase), the hormones in 
saliva are important for defence and repair of the teeth and the 
soft tissues of the oral cavity and upper alimentary tract, the oral 
immune response, inhibiting or activating oral tumours, and for 
some animals acting as pheromones in territorial delineation, 
mating behavior and maternal nursing (2).
In laboratory rats and mice, submandibular glands clearly ex-
hibit regulatory functions on other body functions, organs and 
glands consequent to their secretion into the oral cavity (exo-
crine secretion) and the blood (endocrine secretion). Numerous 
biologically active polypeptides are involved in growth and dif-
ferentiation, enzymatic control, homeostatic regulation, and ad-
aptation to stress (3-5). Dysfunctional salivary glands may facili-
tate the development of the pathologies associated with various 
disorders, such as diabetes mellitus, sensitivity to toxins (6), and 
possibly metabolic syndrome. The endocrine secretions partici-
pate in the maintenance of the integrity of eosphageal and gas-
trointestinal mucosa (7), promote hepatic regeneration (8), are 
essential for maintenance of the reproductive system (9), influ-
ence tumour growth (10,11), modulate the severity of systemic 
inflammatory responses (12), and modulates the responses of 
adipocytes (13) to catecholeamines. Many of these biologically 
active polypeptides are growth factors that are synthesized and 
secreted from the salivary (submandibular) glands as well as 
from adipose tissue (Table 1). Although many adipokines are 
found in saliva to date only a few have been shown to be synthe-
sized and secreted from the salivary glands – leptin (14), inter-
leukin-6 (IL-6) (15) and tumor necrosis factor-alpha (TNF-α) 
(16).
Diseases of human salivary glands arise from a variety of 
causes such as obstruction (stone formation), infection, inflam-
mation, tumors and autoimmunity (Sjögren’s syndrome). These 
diseases generally result in loss of function with decreased saliva 
production and an ensuing complaint of xerostomia, which has 
the following clinical features: (i) increased thirst and fluid in-
take; (ii) difficulty in mastication, swallowing, speech and eating 
of dry food; (iii) burning and tingling sensations in the mouth, 
(iv) oral infections, (v) abnormal taste in the mouth, and (vi) 
painful salivary gland enlargement. If loss of function is pro-
longed the incidence of sialadenitis (inflammation of salivary 
glands), dental caries, periodontal disease and persistent oral 
infections increases, with an associated decline in the quality of 
life (31, 32). 
Unlike rats and mice few systemic functions have been de-
monstrably modified by loss of salivary gland function in hu-
mans, although mucosal integrity is possibly modified by low 
table 1. growth factors secreted from submandibular glands and adipose tissue
Growth Factors Submandibular glands Adipose tissue
Epidermal growth factor (EgF) (17) ?
nerve growth factor (ngF) (18) (19)
Transforming growth factor-alpha (TgF-alpha) (20) (21)
Transforming growth factor-beta (TgF-beta) (22) (21)
basic fibroblast growth factor (bFgF, FgF2 or FgF-β) (23) (24)
Insulin-like growth factors (IgF-I) (25) (26)
brain-derived neurotrophic factor (bDnF) (27) (19)
hepatocyte growth factor (hgF) (28) (29)
vascular endothelial growth factor (vEgF) (30) (24)
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levels of salivary EGF thus contributing to Barrett’s columnar 
lined oesophagus (33, 34). The increases in salivary chromogra-
nin A (35) and IgA (36) (antibacterial and antimicrobial prop-
erties), after upper thoracic massage have been proposed to 
contribute to enhanced immune defence associated with these 
therapies in cancer and HIV patients. Several human systemic 
diseases that affect the oral fluid’s composition include cystic 
fibrosis, multiple sclerosis, graft-versus-host disease, diabetes 
mellitus, alcoholic liver cirrhosis, acquired human immunode-
ficiency syndrome, epilepsy, burning mouth syndrome, kidney 
dysfunction (37) and metabolic syndrome (38). Other causes 
of insufficient saliva production include anxiety, dehydration, 
chemo- and radiation therapy, and some medications such as 
antidepressants, amphetamines and antihistamines. 
Salivary glands and obesity
Obesity per se does not appear to impact dramatically salivary 
gland function. In a recent study (39) rats fed a “cafeteria diet” 
became obese and showed a 20-30% increase in parotid gland 
weight, although the weights of the submandibular and sublin-
gual glands were not altered. The histological organization of 
the glands was not altered in obese rats, although morphometric 
analysis pointed to a reduction in the number of serous acinar 
cells (protein secreting) in the submandibular glands. 
However, parotid gland enlargement is not unique to obesity 
as female patients with psychosomatic eating disorders, such as 
anorexia nervosa and bulimia nervosa (Fig. 1), are also enlarged 
(40). The factors and pathogenesis leading to this enlargement 
have not been identified for these different eating disorders. The 
submandibular glands were not affected. The effect of obesity 
on salivary flow rate is not a settled issue with several groups 
reporting no effect (41,42), and another suggesting a reduced 
flow rate (43). Nonetheless, saliva composition changes in direc-
tions favouring the formation of caries (e.g. decrease in phos-
phate and peroxidase activity with increase in free sialic acid 
and protein (42), thus suggesting detailed studies on saliva com-
position and the proteome are merited in obese individuals. A 
recent study examining the proteome showed that obese sub-
jects with periodontitis had higher levels of neutrophil alpha-
defensins in their saliva compared to non-obese controls (44). 
This result is consistent with inflammatory condition associated 
with obesity. Interestingly, serum alpha-defensins decrease after 
bariatric surgery-induced weight loss (45), suggesting that these 
peptides may represent serum markers of inflammation in obese 
patients (44). Interestingly, a correlation between low plasma 
level of NGF and reduced excretory function of submandibular 
glands was found in patients with advanced stage of metabolic 
syndrome as compared with patients with early stage of meta-
bolic syndrome and with controls (38). This observation in con-
junction with the role of submandibular gland EGF decreasing 
the lipolytic effect of adrenaline (13) suggest that the effects of 
salivary glands and their secreted growth factors on metabolic 
syndrome merit further investigation.
periodontal health and obesity
Since increased prevalence of periodontal disease is a well-
known complication of type 2 diabetes mellitus, and as obesity 
frequently leads toward type 2 diabetes mellitus, the question 
arises: Do obese patients may have exacerbated periodontal dis-
ease?
Both plaque index – reflecting dental plaque, and probing 
depth – a measurement of periodontal pocket, are closely linked 
with periodontal inflammation and infection, and are statisti-
cally associated with high body mass index (BMI) and obesity, 
independently of dietary patterns and insulin resistance. Small 
increases in probing depth values in obese patients possibly in-
dicate an impaired immune response and predisposition to peri-
odontitis (46,47). In addition, patients who have undergone bar-
iatric surgery showed an improved probing depth and clinical 
attachment level response to non-surgical periodontal therapy 
when compared to those did not have such a surgery (48). Sev-
eral meta-analyses have shown a consistent positive association 
between periodontal disease and BMI, although the magnitude 
of the association needs to be quantified, temporal associations 
clarified and mechanisms defined (49, 50). It remains unclear 
Figure 1. parotid cell volume is increased in obese patients 
as well as in non-obese patients with anorexia nervosa and 
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whether obesity is a risk factor for periodontal disease of wheth-
er periodontitis possibly increases the risk of weight gain (49).
metabolic polypeptides in saliva
Numerous metabolic polypeptides are present in saliva and are 
synthesized locally and/or transported from the blood. Recep-
tors for most of these polypeptides are expressed in taste cells 
(TCs): insulin (51), leptin (52), glucagon (53), glucagon-like 
peptide-1 (GLP-1) (54), ghrelin (55), galanin (56), cholecysto-
kinin (CCK) (57), vasoactive polypeptide (VIP) (58, 59), neu-
ropeptide tyrosine (NPY) (60) and polypeptide Y (PYY(3-36) 
(61). Receptors for adiponectin have not been described in taste 
buds but they are present in gingival tissues (62). For the most 
part these polypeptides and their receptors are linked to putative 
roles in the different tastes – sweet (52-54, 59), salty (55), sour 
(54, 55) and umami (63). However, it is only recently that a role 
for one of these peptides in regulating feeding behaviour was 
elucidated (61).
Peptide YY(3-36) is a satiation hormone released postprandi-
ally into the bloodstream from L-endocrine cells in the gut epi-
thelia, and has been associated with conditioned taste aversion 
(64). Salivary PYY(3-36) originates from the blood and is also 
synthesized in cells of the taste buds, and its receptor, Y2R, is 
expressed in the basal layer of the progenitor cells of the tongue 
epithelia and von Ebner’s gland, which are serous salivary exo-
crine glands residing within the moats surrounding the circum-
vallate papillae in the posterior one-third of the tongue. Increas-
ing salivary PYY(3-36), whether acutely with an oral spray or in 
a sustained manner using viral vector-mediated gene delivery to 
salivary glands, alters feeding behavior (61). Oral administered 
peptide induced stronger satiation, and the long-term increase 
mediated with the viral vector reduced food intake and body 
weight in diet-induced obese mice. This study is significant on 
several fronts: (i) the view that PPY(3-36) is thought to con-
tribute to conditioned taste aversion due to its ability to inhib-
its feeding of rodents may actually be a satiation response, (ii) 
a potentially simple and efficient therapeutic approach for the 
treatment of obesity may be developed, and (iii) feeding studies 
with other metabolic polypeptides may have to be re-evaluated.
Saliva as a diagnostic tool: an adipokine insight 
The argument is frequently made that since saliva is an easy 
to obtain biological fluid and can be collected non-invasively, 
measurements of salivary hormonal changes should be preferred 
in diagnoses and treatments. Saliva collection would not burden 
healthcare with additional costs, and it can be collected readily 
by patients at home and at various times of the day. However, 
saliva is not a mainstream sample source for hormone analysis, 
although for specific investigations in psychiatry, stress research, 
and pharmacokinetics, saliva analysis delivers very reliable re-
sults (65). 
 For the adipokines the claim is also made that determination 
of their levels in saliva would contribute significantly to under-
standing their physiology and role in several clinical conditions 
such as obesity, insulin resistance, inflammation, reproduction, 
and stress responses (66). Adiponectin has received the most 
attention since a significant correlation exists between plasma 
and salivary adiponectin levels. Since obese, type 2 diabetes and 
metabolic syndrome patients have decreased levels of plasma 
adiponectin (67), nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) (68), salivary adiponectin, NGF 
and BDNF may be a useful measure of increased cardiometabo-
ic risk (69). A significant negative correlation is found between 
plasma adiponectin levels and BMI (70). However, correlations 
between plasma and saliva adiponectin levels do not exist with 
several different methods of collecting adiponectin (70), and a 
factor exists in saliva that elutes with adiponectin and acts as an 
inhibitor of adiponectin binding (71). The issues surrounding 
the measuring of salivary adiponectin are not settled. Thus, there 
are many encumbrances to making saliva a mainstream sam-
ple source for both research and clinical analysis of adipokines. 
These encumbrances include: (i) assay validation in terms of 
hormone recovery, linearity, accuracy and precision; (ii) the 
need to develop specific and standardized collection methods, 
and analytical tools; (iii) the establishment of defined reference 
intervals; (iv) validation in and implementation of round-robin 
trials (inter-laboratory testing performed independently several 
times); (v) overcoming the significant issue of patient compli-
ance in issues related to collection times, methods and sample 
handling, and (vi) acceptance over the long term of these meth-
ods by clinicians. Even with these cautionary notes future stud-
ies may reveal one or more of salivary adipokines (66), proteins 
(e.g. C-reactive protein) and enzymes (e.g. lysozyme) (72), and/
or metabolites (e.g. uric acid) (73) that eventually may be useful 
for studying, diagnosing and treating metabolic syndrome and 
obesity.
treatment of radiation-induced salivary dysfunction
The primary treatments for managing head and neck cancer are 
radiation therapy or surgery, or both combined. Chemotherapy 
is used as an additional, or adjuvant, treatment. The side effects 
of radiation therapy include sore throat, loss of taste sensation 
and dryness of the mouth, with the latter effects resulting from 
radiation-induced salivary dysfunction can be particularly se-
vere and problematic in the long term. To minimize these sali-
vary gland problems the clinical focus has been on intensity-
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modulated radiation therapy (IMRT) over two-dimensional ex-
ternal beam radiotherapy (EBRT) as a means to spare the major 
salivary glands and prevent intractable hyposalivation. Several 
clinical studies have shown that IMRT of oropharyngeal and hy-
popharyngeal cancers results in a significant reduction in grade 
2 xerostomia (moderate dryness of the mouth, poor response to 
stimulation) over patients receiving standard EBRT (see (74)). 
Although these results are promising alternative treatment strat-
egies for xerostomia are required since IMRT does not totally 
spare the salivary glands and is not always available as a treat-
ment option. Furthermore, many of the more than half-million 
patients treated each year with head and neck cancer will suffer 
from radiation-induced salivary gland dysfunction consequent 
to a reduction in function and number of acinar cells and mor-
phological deterioration consequent to inflammation and fibro-
sis (75,76). Various pharmaceutical treatment strategies (adren-
ergic and muscarinic receptor agonists) (75) and basic fibroblast 
growth factor (77) can reduce radiation-induced xerostomia, 
but these treatments cannot address the patients already suffer-
ing irreversible hyposalivation.
Based on advances in using adipose stem cells in a wide vari-
ety of therapeutic conditions (78), including their neuroregen-
erative potential (79), these stem cells were given to mice with 
radiation-induced xerostomia (80). Adipose-derived stromal 
cells (ADSC) significantly improved salivary flow rate in mice 
when implanted into submandibular glands as late as 10 weeks 
after 10 Gy irradiation treatments (Fig. 2). Some significant fea-
Figure 2. saliva flow from irradiated submandibular glands is 
partially restored by transplantation of adipose derived stem 
cells (aDsc) into the glands 10 weeks after irradiation. saliva 
flow rate was measured for 30 minutes after pilocarpine injec-
tion on day 0, and at 5, and 10 weeks. adapted and modified 
from (80).
tures of this ADSC treatment are: (i) it occurs rapidly, within 1 
month of transplantation, (ii) the ADSC differentiate into blood 
endothelial cells and ductal cells, and (iii) the ADSC appear to 
act by improving blood flow, probably consequent to the strong 
angiogenic capabilities of these cells with their expression and 
release of growth factors, such as VEGF and HGF. Some out-
standing issues that remain to be resolved are: (i) why is there 
an increase in saliva flow given that ADSC did not differentiate 
into acinar cells, and (ii) the possibility of tumor growth with 
this stem cell therapy. 
This technological approach is significant as it provides a 
means to improve severe intractable salivary gland dysfunction 
and can be administered shortly or years after the radiation-in-
duced damage has occurred.
Conclusion
The salivary glands and their “classical” functions – protecting 
the oral cavity, maintaining a moist mouth, and aiding in diges-
tion – do not appear to be seriously compromised by obesity, 
although obese patients would be advised to pay attention to 
their oral health due to a higher incidence of periodontal dis-
ease. Sialoadenectomy has been a useful tool for revealing the 
role of salivary glands in systemic health (81,82), and such a 
“knockout” experimental approach has not yet been applied to 
studying the roles of the salivary glands on the development of 
obesity and metabolic syndrome. A true understanding of sali-
vary gland function in obesity and its related diseases lies in the 
future if indeed factors released from these glands participate 
in the satiety and inflammatory responses, offering an avenue 
for the treatment of these diseases. From the opposite direction 
adipose tissue may provide therapeutic benefit to dysfunctional 
salivary glands as transplantation of ADSC may eventually be 
useful for the treatment of intractable irradiation-induced xeros-
tomia. Last not least, (i) the introduction of salivary determina-
tions of adipokines could contribute to the study of pathogenesis 
of various obesity-related diseases, and (ii) the role of adipose 
tissue associated with salivary glands should also be studied.
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